Literature DB >> 7995636

Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats.

Y Uehara1, N Hirawa, Y Kawabata, T Suzuki, N Ohshima, K Oka, T Ikeda, A Goto, T Toyo-oka, K Kizuki.   

Abstract

We investigated whether long-term infusion of kallikrein would attenuate renal injury in salt-induced hypertension in Dahl salt-sensitive rats. A subdepressor dose of purified rat urinary kallikrein (700 ng/d IV) was infused by osmotic minipump for 4 weeks in male Dahl salt-sensitive rats fed a high salt (2% NaCl) diet. This dose did not affect the time-dependent elevation of blood pressure; however, urinary protein excretion was significantly decreased, and glomerular filtration rate was increased. These beneficial effects were reflected morphologically by an attenuation of glomerulosclerotic lesions and tubular injury seen in the hypertensive Dahl salt-sensitive rats. Kallikrein infusion increased urinary excretion of bradykinin and stimulated excretion of cyclic GMP, suggesting that the kallikrein-kinin-prostaglandin and nitric oxide axes were enhanced by rat urinary kallikrein infusion. The alterations induced by kallikrein infusion were potentiated by the concomitant administration of the angiotensin-converting enzyme inhibitor alacepril. These studies indicated that long-term replacement with rat tissue kallikrein attenuates renal injury in hypertensive Dahl salt-sensitive rats.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7995636     DOI: 10.1161/01.hyp.24.6.770

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  6 in total

Review 1.  Kallikrein-kinin in stem cell therapy.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

2.  Modulation by nitric oxide and prostaglandin of the renal vascular response to angiotensin II (3-8).

Authors:  M Yoshida; M Kikukawa; H Hisa; S Satoh
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 3.  The kallikrein-kinin system in health and in diseases of the kidney.

Authors:  Masao Kakoki; Oliver Smithies
Journal:  Kidney Int       Date:  2009-02-04       Impact factor: 10.612

4.  Effects of hydrogen-rich water on abnormalities in a SHR.Cg-Leprcp/NDmcr rat - a metabolic syndrome rat model.

Authors:  Michio Hashimoto; Masanori Katakura; Toru Nabika; Yoko Tanabe; Shahdat Hossain; Satoru Tsuchikura; Osamu Shido
Journal:  Med Gas Res       Date:  2011-11-03

5.  Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors.

Authors:  Xavier Charest-Morin; Arvind Raghavan; Matthew L Charles; Tadeusz Kolodka; Johanne Bouthillier; Mélissa Jean; Mark S Robbins; François Marceau
Journal:  Pharmacol Res Perspect       Date:  2015-02-10

Review 6.  Genetically‑modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)‑based targeted therapy (Review).

Authors:  Marina Devetzi; Maria Goulielmaki; Nicolas Khoury; Demetrios A Spandidos; Georgia Sotiropoulou; Ioannis Christodoulou; Vassilis Zoumpourlis
Journal:  Int J Mol Med       Date:  2018-01-03       Impact factor: 4.101

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.